Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Director John Neuman recently purchased 40,000 shares of SeaStar Medical (TASE:BLWV) Holding Corp (NASDAQ:ICU) common stock, according to a Form 4 filing. The transactions, which occurred on June 24, 2025, involved the purchase of shares at a weighted average price of $0.3599, resulting in a total value of $14,396. This insider purchase comes as the stock shows signs of recovery, posting a 19% gain over the past week, though it remains down 79% over the past six months. According to InvestingPro analysis, the stock is currently trading below its Fair Value, with technical indicators suggesting oversold conditions.
The prices paid for the shares ranged from $0.359 to $0.36. With a market capitalization of just $6.78 million, SeaStar Medical represents a micro-cap opportunity that warrants careful analysis. Discover 14 additional key insights about ICU with InvestingPro’s exclusive research report. Following this transaction, Neuman directly owns 80,000 shares of SeaStar Medical Holding Corp.
In other recent news, SeaStar Medical Holding Corporation has made significant strides in its operations and financial strategy. The company announced a $4 million public offering of common stock and warrants, which is part of its efforts to regain Nasdaq compliance by meeting the $2.5 million stockholders’ equity requirement. This offering, priced at $0.65 per share, is expected to close soon, with H.C. Wainwright & Co. acting as the exclusive placement agent. SeaStar Medical has also secured a grant from the U.S. Department of Defense for burn treatment research using its Selective Cytopheretic Device (SCD) therapy. Additionally, the Centers for Medicare & Medicaid Services (CMS) will cover expenses for Medicare and Medicaid patients in SeaStar’s NEUTRALIZE-CRS clinical trial, which investigates the efficacy of SCD therapy in reducing hyperinflammation in acute heart failure patients. The company has also reported increased adoption of its FDA-approved QUELIMMUNE therapy for pediatric acute kidney injury. These developments highlight SeaStar Medical’s ongoing efforts to enhance its financial stability and expand the clinical application of its therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.